Clinically significant cancer detected in more men in MRI-targeted biopsy versus standard-biopsy group
MONDAY, March 19, 2018 (HealthDay News) — For men with a clinical suspicion of prostate cancer, magnetic resonance imaging (MRI)-targeted biopsy is noninferior to standard biopsy, according to a study published online March 19 in the New England Journal of Medicine to coincide with the annual meeting of the European Association of Urology, held from March 16 to 20 in Copenhagen, Denmark.
Veeru Kasivisvanathan, M.B.B.S., from the University College London, and colleagues conducted a multicenter, noninferiority trial involving 500 men with a clinical suspicion of prostate cancer who were randomized to undergo MRI, with or without targeted biopsy (252 men), or standard transrectal ultrasonography-guided biopsy (248 men).
The researchers found that 28 percent of men in the MRI-targeted biopsy group had MRI results that were not indicative of prostate cancer and did not undergo biopsy. Clinically significant cancer was detected in 38 percent of men in the MRI-targeted biopsy group and in 26 percent of the standard-biopsy group (adjusted difference, 12 percentage points; 95 percent confidence interval, 4 to 20; P = 0.005). MRI, with or without targeted biopsy, was noninferior to standard biopsy; superiority of this strategy was indicated by the 95 percent confidence interval.
“The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonography-guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously,” the authors write.
Several authors disclosed financial ties to the pharmaceutical, medical device, and medical technology industries.
Copyright © 2018 HealthDay. All rights reserved.
